Bristol Myers Squibb Partners with Microsoft to Enhance AI in Healthcare
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Source: Fool
- AI Healthcare Collaboration: Bristol Myers Squibb's partnership with Microsoft aims to leverage imaging technology used in 80% of U.S. hospitals to create an AI-enabled workflow for earlier lung cancer diagnosis, enhancing treatment efficiency and potentially expanding to other indications.
- Market Performance Analysis: While Nvidia thrives in the market, Bristol Myers Squibb offers a 4.6% dividend yield and a low P/E ratio of 18, indicating its attractiveness for long-term income investors and potentially signaling a buying opportunity.
- Surgical Robot Demand Growth: Intuitive Surgical's da Vinci surgical robots saw a 13% increase in installations from 2024 to 2025, with a 19% rise in surgeries performed using these robots, reflecting strong market demand and suggesting significant future growth potential.
- FDA Approval for AI Technology: Intuitive Surgical received FDA approval in late 2025 to integrate real-time AI imaging technology into its robots for lung surgery, addressing the challenge of lung movement during procedures and paving the way for fully automated surgeries, which could further drive company growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 55.86 USD with a low forecast of 37.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 55.560
Low
37.00
Averages
55.86
High
68.00
Current: 55.560
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Administration Launches Medicare Drug Price Negotiations
- Expansion of Drug Negotiations: The Trump administration has expanded Medicare drug price negotiations to include treatments administered in doctors' offices for conditions such as diabetes and HIV, affecting 15 drugs set to take effect in 2028, aiming to reduce out-of-pocket costs for beneficiaries.
- Spending Overview: According to the Centers for Medicare and Medicaid Services, approximately 1.8 million beneficiaries utilized these medications between 2024 and 2025, accounting for about $27 billion in spending, highlighting the significance of Medicare expenditures in drug price negotiations.
- Pharmaceutical Impact Assessment: Analysts indicate that for 14 of the drugs, only Gilead's Biktarvy significantly impacts the company's estimated 2027 global sales, representing around 8%, while other drugs' Medicare revenue exposure is limited to 0% to 3%, suggesting minimal overall revenue impact for pharmaceutical companies.
- Kaiser Settlement on Fraud: Kaiser Permanente has agreed to a historic $556 million settlement over Medicare Advantage fraud allegations, reflecting the government's stringent enforcement stance on Medicare fraud, which could have far-reaching implications for the industry.
Continue Reading
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives on their outlooks, which could influence investor decisions.
- Market Reaction Insight: While specific rating changes are not detailed, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor these shifts.
- Investor Guidance: When considering the purchase of GM stock, analysts' insights may provide crucial reference points, aiding investors in making more informed investment choices.
- Source of Rating Changes: Comprehensive information on all analyst rating changes can be found on the analyst ratings page, ensuring investors stay updated with the latest market insights.
Continue Reading